Skip to main content
METABIOMED.CO.,LTD logo

METABIOMED.CO.,LTD — Investor Relations & Filings

Ticker · 059210 ISIN · KR7059210005 KO Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2023-03-13 Notice of Dividend Amou…
Country KR South Korea
Listing KO 059210

About METABIOMED.CO.,LTD

https://www.meta-biomed.com/

METABIOMED.CO.,LTD. is a developer and manufacturer of medical devices and biomaterials. The company's operations are organized into four primary business areas: Dental, Suture Material & Biomaterial, Meta Surgical, and Cosmetic Medical. Its dental division provides a range of equipment and materials, with its root canal filling product holding the largest global market share. The company also manufactures various synthetic absorbable surgical sutures, including Poliglecaprone (PGCL) and Polydioxanone (PDO) types. The surgical division offers devices for use in general surgery, orthopedics, neurosurgery, and obstetrics & gynecology. In the cosmetic medical field, it produces products such as PDO threads. METABIOMED distributes its products to over 100 countries through a global sales network.

Recent filings

Filing Released Lang Actions
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement regarding a 'Cash/In-kind Dividend Decision' (현금ㆍ현물배당 결정) by Meta Biomed. It specifies the dividend amount per share, the record date, the payment date, and the approval process via the general meeting of shareholders. This fits the definition of a Notice of Dividend Amount (DIV).
2023-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Meta Biomed regarding a significant change in revenue or profit structure (30% or more). This is a standard disclosure requirement in South Korean financial markets (DART system) when a company's financial performance deviates significantly from the previous period. Since it provides key financial highlights and explanations for the variance rather than being a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial results. FY 2022
2023-03-13 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Meta Biomed regarding a 'New Facility Investment' (신규시설투자등). It details a correction (정정신고) to a previously filed investment plan, specifically updating the investment amount and the project completion date. This type of disclosure regarding capital expenditure and facility investment falls under general regulatory filings as it does not fit into specific categories like M&A, dividends, or share repurchases.
2022-12-22 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and the closure of the shareholder register for the purpose of holding an upcoming Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal notification of a corporate action. Given it is a standard regulatory disclosure regarding shareholder rights and meeting preparation, it fits best under the RNS category.
2022-12-14 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the share transactions (purchases) made by an executive (Oh Ji-soo) of Meta Biomed. This type of filing is a standard disclosure for insider trading/director dealings, which corresponds to the 'Director's Dealing' category.
2022-12-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (장내매수 - open market purchases) of a company executive (Oh Ji-soo) at Meta Biomed. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2022-12-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.